Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
Ramaswamy Govindan(Washington University in St. Louis), Martin Reck(German Center for Lung Research), Pieter E. Postmus(Leiden University Medical Center), Doina Ganea(Temple University), Baohui Han(Shanghai Jiao Tong University), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Kenneth J. O’Byrne(Translational Research Institute), Myung‐Ju Ahn(Sungkyunkwan University), Justin Kopit(Gdańsk Medical University), Marina Tschaika(Bristol-Myers Squibb (United States)), Claus-Peter Schneider(Washington University in St. Louis), Mingshun Li(Gdańsk Medical University), Takayasu Kurata(Kansai Medical University), Vladimir Vladimirov(Pyatigorsk Oncology Center), Natalia Fadeeva(Gdańsk Medical University), Pablo Fernando Gonzalez Mella(Gdańsk Medical University), Fabrice Barlési(Hôpital Nord), Li Zhang(Gdańsk Medical University), Tomohide Tamura(St. Luke's International Hospital), Jacek Jassem(Gdańsk Medical University), Aleksandra Szczęsna(Chinese University of Hong Kong), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 380
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k